PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats
about
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeysRecent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug developmentDifferential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeysEffects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuseBeyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug designPhenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in ratsOpposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats.Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.Intracranial self-stimulation to evaluate abuse potential of drugs.Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administrationThe anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in rats.A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in miceCocaine self-administration in dopamine D₃ receptor knockout mice.Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in ratsDopamine D3 receptors regulate reconsolidation of cocaine memory.Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats.The selective D₃ receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preferenceEffects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats.Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats.Pathological gambling in Parkinson's disease--a review of the literature.Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.Dopamine D3 receptor antagonists: a patent review (2007 - 2012).Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.The dopamine D3 receptor, a quarter century later.Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.Nucleus accumbens hyperpolarization-activated cyclic nucleotide-gated channels modulate methamphetamine self-administration in rats.Abstinence to chronic methamphetamine switches connectivity between striatal, hippocampal and sensorimotor regions and increases cerebral blood volume response.
P2860
Q24598398-62377223-77EE-4423-A792-6EE8ABB63ACCQ27014737-DB3100DB-2569-4BF4-A60F-69F180C53FB6Q27305163-544ECCD6-B54E-4874-9BB1-5E9284484115Q27310677-85FC45E3-F359-4B17-846A-ECE0A7BB09F6Q28067056-5431FE59-21EE-4008-B150-46B0A00F7BDBQ28275963-108CBD99-F483-4B04-8983-2639D03ED42AQ28828620-EC67AD72-424B-4E28-A513-3ECA6AC66851Q30581703-9C858360-68FC-4C50-9390-DB93AB57F607Q30764851-B01C8A27-A140-4500-BFF3-25E9EF2F74CDQ30855960-0454640F-DC4B-4EBC-95CF-26611399AAB0Q33697312-2BA75584-37F5-4865-B61B-1B7B76895F07Q33768609-E29F557A-90D7-49F7-913D-D649F57FABADQ33845750-883CA9F9-7A8B-4ED2-80C1-8708F55140B0Q34104379-26CC1CB3-3110-414E-88B6-F641B99BDF84Q34231896-EE523BDD-62D2-47E8-A83E-78E55A21BEF5Q35151502-1CEE4AD0-6787-49C3-8C49-51EE70292AAAQ35200015-9D1BE1FE-BEED-4ACD-BF80-736E90D00F83Q35892818-A30E2D2F-191A-4E4C-8AFD-5D27A5078B65Q36248887-868C0778-3C42-4884-A001-5DF21A26A06DQ36579310-665AA497-C69C-4C2B-B799-9D8B203D13C0Q36655271-86E54F92-6232-4A13-8ED4-74CF7DBC4CB7Q36771943-C23A995A-6B27-4E0E-8462-DABC06802317Q36823743-1B99822E-586D-4672-B3AA-CD26F17F87E9Q37025051-D38ECA70-2CE1-4F33-89C4-F94A380FD116Q37027008-CB9E9F7D-3719-4B5C-9B03-700662FCD0CDQ37057438-7826572B-CA2E-4AD1-9748-5D890E507EA7Q37057993-857F099A-745E-4E6B-AD8F-6EDC576AA9F8Q37238225-52BEF46D-6F6E-4647-AB2D-8EC6EB6287CFQ37252065-E763D76C-A930-40AF-9D03-DD05CCD8125EQ37401673-5BC2121D-8A80-42C2-AECB-0067736AB749Q37887679-AC2780D8-2AFB-4499-8499-46659A17B1D7Q38056059-8FE1E80F-E2DA-4DE8-8013-BD7E9BC397A3Q38071135-48D8B7D9-E91F-4F68-B95F-A256BF9DB540Q38173012-0D44B234-2F17-4737-A0A5-E4095CDA6E22Q38335806-82CABC4C-2E35-4E75-ACEC-7CAB0D8EFD36Q38947750-854DA461-BA66-4A7A-9F2D-CB84261A9EE2Q39034288-741B167F-E8CA-4EFC-B3FB-E9F8F07E25D0Q42035376-0CB958FD-310D-41E6-BC82-446CE05C61B7Q47418666-9DDB69D6-B0E7-420D-8066-1C25B97FA398Q52666567-AEB338BF-2262-4EA9-9971-89E19677DA54
P2860
PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PG01037, a novel dopamine D3 r ...... cts of methamphetamine in rats
@en
PG01037, a novel dopamine D3 r ...... ts of methamphetamine in rats.
@nl
type
label
PG01037, a novel dopamine D3 r ...... cts of methamphetamine in rats
@en
PG01037, a novel dopamine D3 r ...... ts of methamphetamine in rats.
@nl
prefLabel
PG01037, a novel dopamine D3 r ...... cts of methamphetamine in rats
@en
PG01037, a novel dopamine D3 r ...... ts of methamphetamine in rats.
@nl
P2093
P2860
P356
P1476
PG01037, a novel dopamine D3 r ...... cts of methamphetamine in rats
@en
P2093
Amanda E Higley
Eliot L Gardner
Krista Spiller
Peter Grundt
Stephen W Kiefer
Zheng-Xiong Xi
P2860
P304
P356
10.1177/0269881109358201
P407
P577
2010-02-08T00:00:00Z